Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study

Feiner, Joshua; McNurlan, Margaret A.; Ferris, Robert; Mynarcik, Dennis C.; Gelato, Marie C.

doi:10.1111/j.1463-1326.2006.00681.x

Cited by 10 publications

(12 citation statements)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no changes in Rd, HOMA-IR or glucose AUC following ingestion of 75g glucose in either the chromium-supplement or placebo groups. This finding is very different from our pilot study which demonstrated a 25% increase in insulin sensitivity with the same time period and same treatment of 1000μg of chromium as chromium picolinate per day in subjects with HIV disease-associated insulin resistance [33]. The discrepancy between the initial study and the current one may arise from the greater number of subjects in the present study, but it is also possible that the result is due to the greater insulin resistance in the subjects of the pilot study (average Rd = 4.5) and the present study (average Rd=7.9).…”

Section: Discussioncontrasting

confidence: 89%

“…The present study is limited by the small number of subjects [39] and the relatively short duration of the trial (8 weeks); although, in our pilot study, 8 weeks was sufficient to observe significant improvement in insulin sensitivity [33]. In human studies, compliance is always a concern, however the data on pill counts suggests that the most of the study subjects were at least 80% compliant in taking the study drug.…”

Section: Discussionmentioning

confidence: 98%

“…Although it is possible that an 8-week trial compared with the 16-week trial reported by Aghdassi et al [54] was not sufficiently long to demonstrate improved insulin sensitivity. This too seems unlikely since our pilot study employed an 8-week supplementation period and demonstrated significant improvement in insulin sensitivity [33]. …”

Section: Discussionmentioning

confidence: 99%

“…The ability of chromium to improve insulin sensitivity with apparently few serious side effects suggested a possible role for chromium supplementation in subjects with insulin resistance associated with HIV disease. A preliminary, open-label study of 6 subjects given 1000μg chromium picolinate for 8 weeks demonstrated an improvement of 25% in insulin sensitivity [33]. Based on these encouraging preliminary results, the current study was designed as a randomized, double- blind, placebo-controlled, 2-month trial of daily oral 1000μg of chromium picolinate in subjects with HIV disease and impaired glucose tolerance.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Chromium Therapy for Insulin Resistance Associated with HIV-Disease

Nurlan¹

2013

J AIDS Clin Res

View full text Add to dashboard Cite

Objective With the advent of highly active anti-retroviral therapy, HIV disease has become a chronic condition, but with a number of metabolic complications including insulin resistance and diabetes mellitus, dyslipidemia and hypertension and an increased incidence of atherosclerosis. The aim of the current study was to test the safety and efficacy of chromium picolinate for HIV- associated insulin resistance. Materials/Methods The study was a randomized, double-blind, placebo-controlled trial with subjects receiving 500μg of chromium picolinate or placebo twice daily for two months. HIV- infected subjects were selected based on a fasting concentration of plasma glucose greater than 5.5mmol/L or a plasma glucose concentration of greater than 7.7mmol/L (but less than 11mmol/L) 2h after oral ingestion of 75g of glucose. Insulin sensitivity was assessed with a hyper-insulinemic-euglycemic clamp and glucose tolerance was assessed with the oral glucose tolerance test. Subjects were monitored closely for alterations in viral load, CD4+ cells, hemoglobin and hematocrit, kidney and liver function, and fasting lipid profiles. Results Forty-three subjects were enrolled and 39 completed the protocol (20 in the chromium-supplemented and 19 in the placebo arm). Following chromium-supplementation, there were no significant changes in either insulin sensitivity or glucose tolerance. There was a significant improvement in serum HDL cholesterol concentration in the group supplemented with chromium. Conclusions Chromium picolinate supplementation at this level was well-tolerated, but overall was not an effective therapy for insulin resistance in these HIV-infected subjects.

show abstract

Section: Discussioncontrasting

confidence: 89%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chromium Therapy for Insulin Resistance Associated with HIV-Disease

Nurlan¹

2013

J AIDS Clin Res

View full text Add to dashboard Cite

show abstract

“…Another review involving a total of 1690 subjects suggested that 13 out of 15 studies (including 11 randomized, controlled studies) reported significant improvement in at least one outcome of glycemic control [20]. Other reports suggest that chromium may have more consistent effects in certain clinical states and conditions such as insulin resistance or poorer glycemic control [20][21][22][23][24][25][26].…”

Section: Chromium Supplementation In Humans: Review Of Clinical Trialsmentioning

confidence: 99%

Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance

2010

View full text Add to dashboard Cite

Chromium has been established to be an essential trace element in mammals in regard to maintenance of normal carbohydrate metabolism. Studies that provided chromium to human subjects in documented deficiency states noted improved glucose levels. However, controversy exists as to whether dietary supplementation with chromium should be routinely recommended in subjects without documented deficiencies. Over the recent past, several well-designed clinical trials have provided evidence in favor of and against a beneficial effect of chromium. It appears that across all subject phenotypes (eg, lean and obese, insulin sensitive and insulin resistant), a consistent significant and beneficial effect of chromium may not be observed. Specifically, recent data fail to demonstrate significant improvement in carbohydrate metabolism in individuals with metabolic syndrome, impaired glucose tolerance, or consistently in individuals with type 2 diabetes. However, patient selection may be an important factor in determining clinical response, as it was concluded that a clinical response to chromium (ie, decreased glucose and improved insulin sensitivity) may be more likely in insulin-resistant individuals with type 2 diabetes who have more elevated fasting glucose and hemoglobin A(1c) levels.

show abstract

Is Chromium(III) Effective as a Therapeutic Agent?

Vincent

2012

The Bioinorganic Chemistry of Chromium

View full text Add to dashboard Cite

Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study

Abstract: The study shows that chromium picolinate therapy improves insulin resistance in some HIV-positive subjects, but with some concerns about safety in this population.

Cited by 10 publications

References 40 publications

Chromium Therapy for Insulin Resistance Associated with HIV-Disease

Chromium Therapy for Insulin Resistance Associated with HIV-Disease

Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance

Is Chromium(III) Effective as a Therapeutic Agent?

Contact Info

Product

Resources

About